# 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

Source: https://onco.cc/trials/nct04689347/  
OnCo record `nct04689347` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of bevacizumab (glioblastoma use), fOLFIRI (5-FU, leucovorin, irinotecan), fOLFOX (5-FU, leucovorin, oxaliplatin) and temozolomide in colorectal cancer, run by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, now recruiting.

## Summary

5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. is a phase 1/2, interventional study registered as NCT04689347 by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, with a registry enrolment figure of 27 participants, started 2021-01-01 and due to reach its primary completion in 2026-04-30. Interventions recorded: Bevacizumab; Irinotecan; Leucovorin; 5Fluorouracil; Temozolomide. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: (Phase 1b) safety and to determine the recommended phase 2 dose of the combination of FLIRT- bevacizumab in patients with MGMT silenced and MSS mCRC, previously untreated for advanced disease. (Phase 2) efficacy of FLIRT/bev. Colorectal eligibility wording from the registry: "Histologically confirmed metastatic adenocarcinoma of the colon and/or rectum". Sites: Italy. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT04689347
- Phase: 1/2
- Setting: Phase 1b/2 Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
- Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Enrolled: 27

## Sources

- ClinicalTrials.gov NCT04689347: https://clinicaltrials.gov/study/NCT04689347

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Temozolomide](https://onco.cc/drugs/temozolomide/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04689347.json